A human SARS-CoV neutralizing antibody against epitope on S2 protein

被引:92
作者
Duan, JZ
Yan, XY [1 ]
Guo, XM
Cao, WC
Han, W
Qi, C
Feng, J
Yang, DL
Gao, GX
Jin, G
机构
[1] Inst Biophys, Natl Lab Biomacromol, Beijing, Peoples R China
[2] Inst Microbiol, State Key Lab Microbial Resources, Beijing, Peoples R China
[3] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China
[4] Inst Microbiol & Epidemiol, Dept Epidemiol, Beijing, Peoples R China
关键词
SARS-CoV; neutralizing antibody; S2; protein; scFv; phage-display library;
D O I
10.1016/j.bbrc.2005.05.089
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An immune antibody phage-display library was constructed from B cells of SARS convalescent patients. More than 80 clones were selected from the library by using the whole inactivated SARS-CoV virions as target. One human scFv, B1, was characterized extensively. The B1 recognized SARS pseudovirus in vivo and competed with SARS sera for binding to SARS-CoV with high affinity (equilibrium dissociation constant, K-d = 105 nM). The B1 also has potent neutralizing activities against infection by pseudovirus expressing SARS-CoV S protein in vitro. Finally, we found that the B1 recognized an epitope on S2 protein, especially within amino acids 1023-1189 of S2 protein. This study not only first made a human neutralizing antibody, which recognized an epitope on S2 protein like natural antibody in sera, but also may help us to better understand the immunological characteristics of SARS protein and SARS vaccine design. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:186 / 193
页数:8
相关论文
共 37 条
[1]  
BORREBAECK CAK, 1995, ANTIBODY ENG, P53
[2]   Use of convalescent plasma therapy in SARS patients in Hong Kong [J].
Cheng, Y ;
Wong, R ;
Soo, YOY ;
Wong, WS ;
Lee, CK ;
Ng, MHL ;
Chan, P ;
Wong, KC ;
Leung, CB ;
Cheng, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) :44-46
[3]   Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: Perspective for SARS vaccine development [J].
Choy, WY ;
Lin, SG ;
Chan, PKS ;
Tam, JSL ;
Lo, YMD ;
Chu, IMT ;
Tsai, SN ;
Zhong, MQ ;
Fung, KP ;
Waye, MMY ;
Tsui, SKW ;
Ng, KO ;
Shan, ZX ;
Yang, M ;
Wu, YL ;
Lin, ZY ;
Ngai, SM .
CLINICAL CHEMISTRY, 2004, 50 (06) :1036-1042
[4]   The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration [J].
DeHart, JL ;
Andersen, JL ;
Zimmerman, ES ;
Ardon, O ;
An, DS ;
Blackett, J ;
Kim, B ;
Planelles, V .
JOURNAL OF VIROLOGY, 2005, 79 (03) :1389-1396
[5]  
DONG Z, 2002, ANTIBODY ENG, P308
[6]   Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].
Drosten, C ;
Günther, S ;
Preiser, W ;
van der Werf, S ;
Brodt, HR ;
Becker, S ;
Rabenau, H ;
Panning, M ;
Kolesnikova, L ;
Fouchier, RAM ;
Berger, A ;
Burguière, AM ;
Cinatl, J ;
Eickmann, M ;
Escriou, N ;
Grywna, K ;
Kramme, S ;
Manuguerra, JC ;
Müller, S ;
Rickerts, V ;
Stürmer, M ;
Vieth, S ;
Klenk, HD ;
Osterhaus, ADME ;
Schmitz, H ;
Doerr, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976
[7]   Protein absorption and ellipsometry in biomaterial research [J].
Elwing, H .
BIOMATERIALS, 1998, 19 (4-5) :397-406
[8]   Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein [J].
Giroglou, T ;
Cinatl, J ;
Rabenau, H ;
Drosten, C ;
Schwalbe, H ;
Doerr, HW ;
von Laer, D .
JOURNAL OF VIROLOGY, 2004, 78 (17) :9007-9015
[9]   Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein [J].
Han, DP ;
Kim, HG ;
Kim, YB ;
Poon, LLM ;
Cho, MW .
VIROLOGY, 2004, 326 (01) :140-149
[10]   Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: Implication for developing SARS diagnostics and vaccines [J].
He, YX ;
Zhou, YS ;
Wu, H ;
Luo, BJ ;
Chen, JM ;
Li, WB ;
Jiang, SB .
JOURNAL OF IMMUNOLOGY, 2004, 173 (06) :4050-4057